Prodigiosin (NSC 47147, BRN 4526727)

Red-pigmented antibiotic. Antimalarial. Immunosuppressive. Apoptosis inducer. Cytotoxic. Induces phosphorylation of p38-MAPK. Antimetastatic. Tumor invasion inhibitor. Induces p21WAF1/CIP1 expression. Anticancer compound. gp91(phox) and iNOS expression inhibitor. mTORC1 and mTORC2 complexe inhibitor. Down-regulates SKP2 to induce p27(KIP1) stabilization.\n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: -20 degrees C\nStable for at least 3 years after receipt when stored at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

045166

Size

250ug

Purity

>95% (HPLC)

References

Product Reference: \n?The Antibiotic Activity of Violacein, Prodigiosin, and Phthiocol: H.C. Lichstein & V.F. Van De Sand; J. Bacteriol. 52, 145 (1946)\n?Antimalarial activity of prodigiosin: A.J. Castro; Nature 213, 903 (1967)\n?T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens: S.B. Han, et al.; Int. J. Immunopharmacol. 20, 1 (1998)\n?Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines: B. Montaner, et al.; Br. J. Pharmacol. 131, 585 (2000)\n?Prodigiosin-induced apoptosis in human colon cancer cells: B. Montaner & R. Perez-Tomas; Life Sci. 68, 2025 (2001)\n?Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1: C. Diaz-Ruiz, et al.; Histol. Histopathol. 16, 415 (2001)\n?Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis: S.B. Han, et al.; JPET 299, 415 (2001)\n?The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK: B. Montaner & R. Perez-Tomas; Toxicol. Lett. 129, 93 (2002)\n?Antimetastatic effect of prodigiosin through inhibition of tumor invasion: J. Zhang, et al.; Biochem. Pharmacol. 69, 407 (2005)\n?The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway: V. Soto-Cerrato, et al.; Biochem. Pharmacol. 74, 1340 (2007)\n?Prodigiosins as anti cancer agents: living upto their name: R. Pandey, et al.; Curr. Pharm. Des. 15, 732 (2009)\n?New insights on the antitumoral properties of prodiginines: R. Perez-Tomas & M. Vinas; Curr. Med. Chem. 17, 2222 (2010)\n?Prodigiosin produced by Serratia marcescens NMCC46 as a mosquito larvicidal agent against Aedes aegypti and Anopheles stephensi: C.D. Patil, et al.; Parasitol. Res. 109, 1179 (2011)\n?Prodigiosin inhibits gp91(phox) and iNOS expression to protect mice against the oxidative/nitrosative brain injury induced by hypoxia-ischemia: C.C. Chang, et al.; Toxicol. Appl. Pharmacol. 257, 137 (2011)\n?Prodigiosin, the red pigment of Serratia marcescens, shows cytotoxic effects and apoptosis induction in HT-29 and T47D cancer cell lines: D. Dalili, et al; Nat. Prod. Res. (Epub ahead of print) (2011)\n?Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax: M. Espona-Fiedler, et al.; Biochem. Pharmacol. 83, 489 (2012)\n?Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells: H.Y. Hsieh, et al.; Br. J. Pharmacol. (Epub ahead of print) (2012)\n?

Alternative Names

NSC 47147, BRN 4526727